Cabaletta Bio, Inc. (CABA)

NMS – Цена в реальном времени. Валюта: USD

3.63

-0.19 (-4.97%)

При закрытии: May 12, 2026, 4:00 PM EDT

3.76

+0.13 (3.58%)

До открытия: May 13, 2026, 5:57 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Cabaletta Bio, Inc. (CABA)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Cabaletta Bio, Inc. (CABA)

Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel

Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting

First Patients Dosed with Cabaletta Bio's Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform

Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should Know

Видео

No Data

Пресс-релизы

Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel

Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting

Search stocks

Cabaletta Bio, Inc. (CABA)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Cabaletta Bio, Inc. (CABA)

Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel

Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting

First Patients Dosed with Cabaletta Bio's Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform

Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should Know

Видео

No Data

Пресс-релизы

Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel

Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting